Nippon Life Global Investors Americas Inc. Reduces Position in Edwards Lifesciences Corporation (EW)

Nippon Life Global Investors Americas Inc. lessened its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 9.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 103,080 shares of the medical research company’s stock after selling 10,170 shares during the quarter. Nippon Life Global Investors Americas Inc.’s holdings in Edwards Lifesciences were worth $11,267,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in EW. Victory Capital Management Inc. boosted its stake in shares of Edwards Lifesciences by 4.6% in the 3rd quarter. Victory Capital Management Inc. now owns 557,773 shares of the medical research company’s stock valued at $60,969,000 after purchasing an additional 24,399 shares in the last quarter. Korea Investment CORP boosted its stake in shares of Edwards Lifesciences by 144.5% in the 3rd quarter. Korea Investment CORP now owns 355,683 shares of the medical research company’s stock valued at $38,880,000 after purchasing an additional 210,200 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its stake in shares of Edwards Lifesciences by 53.3% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 11,991 shares of the medical research company’s stock valued at $1,418,000 after purchasing an additional 4,170 shares in the last quarter. Westpac Banking Corp boosted its stake in shares of Edwards Lifesciences by 13.5% in the 2nd quarter. Westpac Banking Corp now owns 14,214 shares of the medical research company’s stock valued at $1,681,000 after purchasing an additional 1,691 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of Edwards Lifesciences by 41.9% in the 2nd quarter. Principal Financial Group Inc. now owns 465,885 shares of the medical research company’s stock valued at $55,086,000 after purchasing an additional 137,643 shares in the last quarter. 81.63% of the stock is currently owned by hedge funds and other institutional investors.

In related news, CEO Michael A. Mussallem sold 32,900 shares of the stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $106.86, for a total transaction of $3,515,694.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $108.86, for a total value of $576,958.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 172,480 shares of company stock valued at $18,548,810. 2.13% of the stock is currently owned by company insiders.

Shares of Edwards Lifesciences Corporation (NYSE EW) traded up $0.59 during mid-day trading on Monday, hitting $117.00. The stock had a trading volume of 251,041 shares, compared to its average volume of 1,637,781. The company has a current ratio of 3.49, a quick ratio of 2.76 and a debt-to-equity ratio of 0.33. The company has a market cap of $24,634.67, a PE ratio of 32.25, a PEG ratio of 2.09 and a beta of 0.51. Edwards Lifesciences Corporation has a one year low of $81.25 and a one year high of $121.45.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, October 24th. The medical research company reported $0.84 EPS for the quarter, missing analysts’ consensus estimates of $0.86 by ($0.02). The company had revenue of $821.50 million during the quarter, compared to the consensus estimate of $833.85 million. Edwards Lifesciences had a net margin of 22.47% and a return on equity of 27.22%. The business’s revenue was up 11.1% compared to the same quarter last year. During the same period last year, the company earned $0.68 earnings per share. analysts anticipate that Edwards Lifesciences Corporation will post 3.75 EPS for the current year.

Several brokerages recently issued reports on EW. BMO Capital Markets reiterated a “buy” rating and set a $132.00 price target on shares of Edwards Lifesciences in a research report on Friday, September 1st. William Blair reiterated an “outperform” rating on shares of Edwards Lifesciences in a research report on Monday, August 28th. Royal Bank Of Canada reiterated a “buy” rating and set a $130.00 price target on shares of Edwards Lifesciences in a research report on Friday, September 1st. SunTrust Banks set a $124.00 price target on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research report on Wednesday, October 25th. Finally, Morgan Stanley reduced their price target on shares of Edwards Lifesciences from $133.00 to $120.00 and set an “overweight” rating on the stock in a research report on Thursday, October 26th. Seven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $125.53.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.com-unik.info/2017/12/04/nippon-life-global-investors-americas-inc-reduces-position-in-edwards-lifesciences-corporation-ew.html.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

What are top analysts saying about Edwards Lifesciences Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Edwards Lifesciences Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit